BeyondSpring Pharmaceuticals outlines Plinabulin plans, wants marketing partner

Ramon Mohanlal, chief medical officer at BeyondSpring Pharmaceuticals, a clinical stage cancer drug developer, speaks to Informa senior editor and writer Sten Stovall during the BIO-Europe Spring® partnering conference in Stockholm, Sweden, about the group's immuno-oncology portfolio. The New York-based group is currently advancing its lead asset Plinabulin in global Phase III trials in non-small-cell lung cancer (NSCLC), initiating a global Phase III trial in the prevention of docetaxel induced neutropenia, and conducting a Phase Ib/II trial of Plinabulin and Nivolumab in NSCLC.

Interviewer: Sten Stovall – Senior Editor, Pharma Intelligence, In Vivo/Pink Sheet/Scrip
Interviewee: Ramon Mohanlal – Chief Medical Officer, BeyondSpring Pharmaceuticals